Free Nephrology CME

  • FREE

    ScientiaCME Immunology (Kidney Transplant Rejection)

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    CME: Fabry disease: Updates from recent research findings

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.

    After completing this course, physicians will better be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
    • Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
    • Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
    • Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium

    Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 6/25/19
    • Expiration of CME credit: 6/25/21
  • FREE

    Atypical hemolytic uremic syndrome (aHUS): therapeutic updates and optimizing treatment

    Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.

    After completing this course, you will better be able to:

    • Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
    • Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
    • Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
    • Design an evidence-based treatment plan for a patient with aHUS

    Target Audience: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 10, 2019
    • Expiration of CME credit: July 10, 2021
  • FREE

    CME: Management strategies for complications of chronic kidney disease (CKD): anemia and hyperphosphatemia

    Chronic Kidney Disease (CKD) affects about 15% of the general population in the United States according to data from the CDC’s National Health and Nutrition Examination Survey and causes a number of complications with anemia and hyperphosphatemia common among them. Anemia occurs in about 15% of patients and arises from a result of decreased production of erythropoietin (EPO) which signals bone marrow to produce red blood cells, whereas hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-Mineral Bone Disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on usage of phosphate binders (PBs).

    By the end of the session the participant will be able to:

    • Describe common complications that patients with CKD experience
    • Describe management strategies for anemia and hypherphosphatemia of CKD and their impact
    • Determine appropriateness of therapies for anemia and hypherphosphatemia of CKD, given a patient case
    • Describe effective management strategies for monitoring anemia and hyperphosphatemia in patients with CKD, taking into account dialysis status

    Target Audience:

    The following healthcare professionals (HCPs): nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 3/5/2020
    • Expiration of CME credit: 3/5/2022
  • FREE

    CME: Treatment strategies in Fabry disease

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels. A defect in the enzyme alpha galactosidase A results in glycosphingolipid accumulation, ultimately leading to multi-organ dysfunction and the patient’s premature death. Early symptoms, which occur during childhood, involve pain and may include Raynaud phenomenon, paresthesias, and arthralgia in the extremities and proximal limbs, as well as impaired gastrointestinal emptying, resulting in abdominal pain, diarrhea, early satiety, postprandial bloating, nausea, and vomiting. In adulthood, the disease’s impact spreads beyond and begins to affect the cardiac and renal systems.

    By the end of the session the participant will be able to:

    • Describe the importance of quick and accurate Fabry disease diagnosis and treatment.
    • Using established methods, determine likelihood of Fabry disease given a patient case.
    • Appropriately describe available therapies used for treatment of Fabry disease and explain current literature supporting use of those therapies.
    • Design and implement an appropriate therapeutic plan for treatment of Fabry disease.
    • Describe future therapies currently being investigated for the treatment of Fabry disease.

    Target Audience: The following healthcare professionals: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 9/4/19
    • Expiration of CME credit: 9/4/21